Researchers warn of catastrophic consequences from rapidly intensifying threat: 'As a species, we have never confronted anything like this'
Americans born today could "live in a world where the U.S. can only produce half as much of its key food crops," CNN's recent headline read.
The ensuing reporting focused on a groundbreaking study recently published in Nature — one of the most widely cited scientific journals globally — and the outlet described its findings as "stark."
Study authors examined the impacts of rising temperatures through a universally understood and relevant lens: the global food supply.
Put plainly, the researchers' calculations were grim: Every 1°C (1.8°F) increase in average global temperatures will result in a worldwide reduction in food production equivalent to 120 fewer calories per person, per day.
Study author Solomon Hsiang of the Stanford Doerr School of Sustainability broke it down further when discussing their findings. "If the climate warms by 3 degrees, that's basically like everyone on the planet giving up breakfast," Hsiang warned.
It's well-documented that climate-related matters are routinely and misleadingly cast in doubt, framed as a matter of belief rather than settled science.
Not everybody lives in a region routinely walloped by extreme weather — such as wildfires or increased coastal flooding — and the issue can seem abstract, localized elsewhere, or more of a problem for the distant future.
However, food is a great equalizer, something all humans require to survive — farmers have long been ringing the alarm about the impacts of unpredictable weather and temperatures on crop yields.
Professor and food policy expert Tim Lang told CNN that adaptations to fortify the global food supply are halting and insufficient. "The data pile up. The politicians turn a blind eye … Land use is not altering fast or radically enough," he lamented, addressing the speed at which agriculture is adapting to changes in the climate.
Do you worry about how much food you throw away?
Definitely
Sometimes
Not really
Never
Click your choice to see results and speak your mind.
"This is a major problem. It's incredibly expensive. As a species, we have never confronted anything like this."
Experts reiterated that "adaptation" and "mitigation" were critical steps to safeguard crops in an increasingly unpredictable climate, one in which the United States could lose half its crop yields.
Growing your own food is one approach to guard against food supply instability at a personal level, whereas donating to climate-related causes is a good way to make a broader impact.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Some pro athletes keep getting better as they age − neuroscience can explain how they stay sharp
In a world where sports are dominated by youth and speed, some athletes in their late 30s and even 40s are not just keeping up – they are thriving. Novak Djokovic is still outlasting opponents nearly half his age on tennis's biggest stages. LeBron James continues to dictate the pace of NBA games, defending centers and orchestrating plays like a point guard. Allyson Felix won her 11th Olympic medal in track and field at age 35. And Tom Brady won a Super Bowl at 43, long after most NFL quarterbacks retire. The sustained excellence of these athletes is not just due to talent or grit – it's biology in action. Staying at the top of their game reflects a trainable convergence of brain, body and mindset. I'm a performance scientist and a physical therapist who has spent over two decades studying how athletes train, taper, recover and stay sharp. These insights aren't just for high-level athletes – they hold true for anyone navigating big life changes or working to stay healthy. Increasingly, research shows that the systems that support high performance – from motor control to stress regulation, to recovery – are not fixed traits but trainable capacities. In a world of accelerating change and disruption, the ability to adapt to new changes may be the most important skill of all. So, what makes this adaptability possible – biologically, cognitively and emotionally? The amygdala and prefrontal cortex Neuroscience research shows that with repeated exposure to high-stakes situations, the brain begins to adapt. The prefrontal cortex – the region most responsible for planning, focus and decision-making – becomes more efficient in managing attention and making decisions, even under pressure. During stressful situations, such as facing match point in a Grand Slam final, this area of the brain can help an athlete stay composed and make smart choices – but only if it's well trained. In contrast, the amygdala, our brain's threat detector, can hijack performance by triggering panic, freezing motor responses or fueling reckless decisions. With repeated exposure to high-stakes moments, elite athletes gradually reshape this brain circuit. They learn to tune down amygdala reactivity and keep the prefrontal cortex online, even when the pressure spikes. This refined brain circuitry enables experienced performers to maintain their emotional control. Creating a brain-body loop Brain-derived neurotrophic factor, or BDNF, is a molecule that supports adapting to changes quickly. Think of it as fertilizer for the brain. It enhances neuroplasticity: the brain's ability to rewire itself through experience and repetition. This rewiring helps athletes build and reinforce the patterns of connections between brain cells to control their emotion, manage their attention and move with precision. BDNF levels increase with intense physical activity, mental focus and deliberate practice, especially when combined with recovery strategies such as sleep and deep breathing. Elevated BDNF levels are linked to better resilience against stress and may support faster motor learning, which is the process of developing or refining movement patterns. For example, after losing a set, Djokovic often resets by taking deep, slow breaths – not just to calm his nerves, but to pause and regain control. This conscious breathing helps him restore focus and likely quiets the stress signals in his brain. In moments like these, higher BDNF availability likely allows him to regulate his emotions and recalibrate his motor response, helping him to return to peak performance faster than his opponent. Rewiring your brain In essence, athletes who repeatedly train and compete in pressure-filled environments are rewiring their brain to respond more effectively to those demands. This rewiring, from repeated exposures, helps boost BDNF levels and in turn keeps the prefrontal cortex sharp and dials down the amygdala's tendency to overreact. This kind of biological tuning is what scientists call cognitive reserve and allostasis – the process the body uses to make changes in response to stress or environmental demands to remain stable. It helps the brain and body be flexible, not fragile. Importantly, this adaptation isn't exclusive to elite athletes. Studies on adults of all ages show that regular physical activity – particularly exercises that challenge both body and mind – can raise BDNF levels, improve the brain's ability to adapt and respond to new challenges, and reduce stress reactivity. Programs that combine aerobic movement with coordination tasks, such as dancing, complex drills or even fast-paced walking while problem-solving have been shown to preserve skills such as focus, planning, impulse control and emotional regulation over time. After an intense training session or a match, you will often see athletes hopping on a bike or spending some time in the pool. These low-impact, gentle movements, known as active recovery, help tone down the nervous system gradually. Outside of active recovery, sleep is where the real reset and repair happen. Sleep aids in learning and strengthens the neural connections challenged during training and competition. Over time, this convergence creates a trainable loop between the brain and body that is better equipped to adapt, recover and perform. Lessons beyond sport While the spotlight may shine on sporting arenas, you don't need to be a pro athlete to train these same skills. The ability to perform under pressure is a result of continuing adaptation. Whether you're navigating a career pivot, caring for family members, or simply striving to stay mentally sharp as the world changes, the principles are the same: Expose yourself to challenges, regulate stress and recover deliberately. While speed, agility and power may decline with age, some sport-specific skills such as anticipation, decision-making and strategic awareness actually improve. Athletes with years of experience develop faster mental models of how a play will unfold, which allows them to make better and faster choices with minimal effort. This efficiency is a result of years of reinforcing neural circuits that doesn't immediately vanish with age. This is one reason experienced athletes often excel even if they are well past their physical prime. Physical activity, especially dynamic and coordinated movement, boosts the brain's capacity to adapt. So does learning new skills, practicing mindfulness and even rehearsing performance under pressure. In daily life, this might be a surgeon practicing a critical procedure in simulation, a teacher preparing for a tricky parent meeting, or a speaker practicing a high-stakes presentation to stay calm and composed when it counts. These aren't elite rituals – they're accessible strategies for building resilience, motor efficiency and emotional control. Humans are built to adapt – with the right strategies, you can sustain excellence at any stage of life. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Fiddy Davis Jaihind Jothikaran, Hope College Read more: The 'hot hand' is a real basketball phenomenon – but only some players have the ability to go on these basket-making streaks Aaron Rodgers' season-ending Achilles tear resurfaces questions about player safety on artificial turf Olympic athletes excel at their sports but are susceptible to unproven alternative therapies Fiddy Davis Jaihind Jothikaran does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Yahoo
an hour ago
- Yahoo
bioAffinity Technologies Appoints New Members to Board of Directors
Financial and Clinical Leaders Provide Significant Expertise for the Company's Commercial Growth SAN ANTONIO, Texas, August 18, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors. "Mr. Rios' business and financial expertise combined with Dr. Oppenheimer's clinical leadership will be invaluable as we increase sales of CyPath® Lung, develop companion diagnostics for asthma and COPD, and strengthen our financial position," said Maria Zannes, President and CEO of bioAffinity Technologies. Mr. Rios brings more than four decades of executive leadership in corporate finance and governance across industries including biotechnology, medical devices, and large-scale construction. He held financial leadership roles at ILEX Oncology, BioMedical Enterprises and Bartlett Cocke General Contractors and currently serves on the boards of CCC Group and Stem Cell Reserve. His proven track record in guiding companies through growth, capital strategy, and operational excellence will strengthen bioAffinity Technologies' financial foundation. Dr. Oppenheimer is the Director of Clinical Research at Pulmonary and Allergy Associates and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey-Rutgers. He is a leader in the diagnosis and treatment of asthma and COPD and an advisor to pharmaceutical companies focused on lung health. He has participated in more than 180 clinical studies and authored more than 260 publications and led or contributed to numerous clinical guidelines. Dr. Oppenheimer has served in leadership positions with the American Board of Allergy and Immunology, the American Academy of Allergy, Asthma & Immunology, and the American College of Allergy, Asthma & Immunology. His extensive clinical experience will help guide bioAffinity's scientific and clinical strategies, particularly in advancing its companion diagnostics in the pipeline for the growing asthma therapeutics market estimated at $26 billion. bioAffinity Technologies also announced that Gary Rubin stepped down from the Board of Directors for personal reasons and not due to any disagreement with the Company or its operations, policies or practices. "We are grateful to Gary for his valuable contributions to bioAffinity over the past seven years and appreciate his continued support," Ms. Zannes said. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the leadership, strengths and contributions Dr. Oppenheimer and Mr. Rios may bring to the Company in their role as members of the Board of Directors. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the leadership, strengths and contributions Dr. Oppenheimer and Mr. Rios may bring to the Company in their role as members of the Board of Directors and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients. Developed by Fujirebio Diagnostics, Inc., the test is now available nationwide through Labcorp. The test offers results that are comparable to existing methods that support a diagnosis of Alzheimer's disease – cerebrospinal fluid (CSF) testing obtained through lumbar puncture and positron emission tomography (PET) scans – but from a simple blood draw, making it more affordable, more accessible and less invasive. Fujirebio reports that in clinical studies, the test demonstrated a positive predictive value of 92% and a negative predictive value of 97%. "The path to an Alzheimer's diagnosis has long meant a diagnostic journey requiring years of invasive procedures and expensive imaging," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "Clinicians need better ways to diagnose their patients more quickly, enroll them in clinical trials, or start therapies. By offering this FDA-cleared blood test nationwide, Labcorp is leading the way in delivering innovative solutions for Alzheimer's disease and other neurological conditions by helping patients, families and physicians get answers sooner." The launch of this test closely follows the release of a new clinical guideline from the Alzheimer's Association, which supports the use of blood-based biomarkers to help evaluate patients suspected of Alzheimer's disease in specialty care settings. The guideline highlights the growing clinical consensus around these tools and reinforces the importance of expanding access. The Lumipulse pTau-217/Beta Amyloid 42 Ratio is intended for adults aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. It is not intended as a screening or stand-alone diagnostic test and must be interpreted in conjunction with other clinical information of the patient. Once ordered, patients can complete the blood draw in a healthcare provider's office or any of Labcorp's more than 2,200 Patient Service Centers (PSCs) nationwide. The FDA-cleared test builds on and replaces a similar pTau-217/Beta Amyloid 42 Ratio test that the company launched in April 2025. For more information about Labcorp's portfolio of blood-based biomarkers for Alzheimer's disease and dementia, visit About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at View original content to download multimedia: SOURCE Labcorp Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data